ABSTRACT
BACKGROUND: The association between phase II of the motor migratory complex (MMC) and hunger remains poorly understood, which may be important in non-diabetic and diabetic obese subjects where gastric inter-digestive motility has been often reported as impaired. We characterize phase II of the MMC and its predictive power on food intake, weight loss, and glycemia in non-diabetic (OB) and diabetic (DM) obese subjects treated with gastric stimulation for 6 months. METHODS: Twelve OB and 12 DM subjects were implanted with bipolar electrodes connected to a gastric stimulator capable of recording antrum electromechanical activity. RESULTS: The phase II mean interval size and duration increased from 156 ± 121 to 230 ± 228 s and from 98 ± 33 to 130 ± 35 min (p < 0.05) in OB and from 158 ± 158 to 180 ± 112 s and from 77 ± 26 to 109 ± 18 min (p < 0.05) in DM after 6 months. There was a significant trend of meals to interrupt the late rather than the early phase II. Nonlinear regression analysis demonstrated that weight loss in OB was significantly associated with the change in interval size of the late phase II and with phase II duration. In the DM group, weight loss and glycemia were also significantly associated with the change in the interval size of the early phase II. CONCLUSIONS: Gastric stimulation delivered in the digestive period can modify the length of the MMC and the contractility in its longest component, phase II. The duration and contractility of the MMC can determine to some extent future intake and, thus, influence energy balance.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/physiopathology , Eating , Gastrointestinal Motility , Myoelectric Complex, Migrating , Obesity/physiopathology , Adult , Diet Records , Female , Humans , Hunger , Male , Middle Aged , Muscle Contraction , Predictive Value of Tests , Weight LossABSTRACT
Comunicamos nuestra experiencia preliminar y describimos la técnica quirúrgica de la braquiterapia prostática transperineal utilizando semillas de I 125 para el tratamiento del cáncer de próstata localizado. Veinticuatro pacientes fueron tratados con esta técnica con un seguimiento mínimo de 6 meses (6-25). La tolerancia fue excelente, el PSA bajó a niveles de normalidad en el 91,6 por ciento y por debajo de 1 ng/ml en el 40,9 por ciento. Dos pacientes presentaron metástasis al año del implante. Nuestra experiencia preliminar a corto plazo nos estimula a seguir a estos pacientes para establecer el rol de esta técnica en el tratamiento del carcinoma de próstata localizado(AU)
Subject(s)
Humans , Male , Prostatic Neoplasms/surgery , Prostatic Neoplasms/therapy , Prostatic Neoplasms/diagnostic imaging , Brachytherapy/instrumentationABSTRACT
Comunicamos nuestra experiencia preliminar y describimos la técnica quirúrgica de la braquiterapia prostática transperineal utilizando semillas de I 125 para el tratamiento del cáncer de próstata localizado. Veinticuatro pacientes fueron tratados con esta técnica con un seguimiento mínimo de 6 meses (6-25). La tolerancia fue excelente, el PSA bajó a niveles de normalidad en el 91,6 por ciento y por debajo de 1 ng/ml en el 40,9 por ciento. Dos pacientes presentaron metástasis al año del implante. Nuestra experiencia preliminar a corto plazo nos estimula a seguir a estos pacientes para establecer el rol de esta técnica en el tratamiento del carcinoma de próstata localizado
Subject(s)
Humans , Male , Brachytherapy/instrumentation , Prostatic Neoplasms , Prostatic Neoplasms/surgery , Prostatic Neoplasms/therapyABSTRACT
Derivatization of rolipram led to the identification of 3-[4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxo-pyrrolidin-1-yl]-5-( 3- methoxybenzyloxy)-benzoic acid N',N'-dimethylhydrazide (4), a potent and selective inhibitor of PDE4, which inhibits the activation of human leukocytes with pIC50 values in the range of 7.3-7.8, and blocks antigen induced eosinophilia in Brown Norway rats at a dose of 1 mg/kg (i.t.).
